Clinical Trials for cancer have evolved from being viewed as a last-ditch effort to the best chance of [a patient] getting cured. With the global pandemic bringing forth a relaxation in regulations from Agencies worldwide, the industry is currently asking itself what the future of oncology trial design and execution really looks like. How might new approaches in decentralized trials be done safely and effectively while also opening up the opportunity to tackle the traditional challenges associated with trial recruitment, engagement, diversity, and patient access? At the same time, there is a clinical rational for earlier phase trials in breakthrough therapies via IO, and novel approaches to trial design in the era of Precision Medicine and Biomarker Driven Therapies.
Join senior decision makers in clinical development to explore the benefits, opportunities and strategies to drive novel design approaches, evolve with the scientific landscape for cancer therapies, and accelerate breakthrough treatments to the patient.
- What are the Lessons to be Learned from Ongoing Clinical Trials for Cancer Patients During the Global Pandemic?
- Develop Regulator Strategies For Early Stages of Development to Understand What it Takes to Get New Products Approved
- Understand how Under-representation of Minority Populations on Cancer Clinical Trials Impacts the Validity Of Trial Results and Can Exacerbate Health Disparities
- Discuss How To Best Design Trials in The Age of Innovation
- What is The Impact of “Big Data” and Data Analytics on Trial Design and Execution?
Event Sponsors
Featured Speakers
Michel Azoulay MD
Senior Medical Director Oncology
Kyowa Kirin
Amy Abernethy MD, PhD
Principal Deputy Commissioner, Acting CIO
US Food & Drug Administration (FDA)
Dr. Kevin Knopf MD
Division Chief Hematology/Oncology
Highland Hospital/ Alameda Health System
David S. Hong MD
Associate Vice President of Clinical Research
M.D. Anderson Cancer Center
Laurie Smaldone MD
CMO/CSO
NDA Group
Marcel Rozencweig
CMO
NeoTX Therapeutics
Caroline Germa
Vice President, Head Clinical Development, Early Portfolio, Oncology R&D
AstraZeneca
Marvella E. Ford, PhD
Associate Director, Population Sciences and Cancer Disparities; SmartState Endow
Hollings Cancer Center; University of South Carolina and South Carolina State University
Melissa Gonzales
Inclusion Principal, External Partnering
Genentech
Gracie Lieberman
Senior Director Regulatory Policy
Genentech
Lola Fashoyin-Aje
Deputy Division Director (acting) & Assoc. Dir, Science & Policy to Address Disp
Food and Drug Administration
David Thompson
Senior Vice President, Real World Research
Syneos Health
Ann Collins
Vice President, Clinical Development
Syneos Health
Kieron Lewis
Business Development Director
Clinigen
Craig Lipset
Assistant Professor of Health Informatics
Rutgers University
Kenneth G. Faulkner PhD
Vice President of eCOA Scientific Services
ERT
Sandra Vingerhoedt
Clinical Project Manager
Bayer AG, Belgium
Create New Relationships that Deliver the Highest Value for your Current Networking Needs with:
LIVE event. No pre-recorded sessions
Social: Real-time Q&A between speakers and attendees during sessions, live polling, and direct messaging capability between attendees
Enhanced Networking: automated matchmaking suggestions based on your goals & interests. Use our virtual “meeting rooms” and set up 1:1 meetings.
Breakout networking rooms and room “hopping” capability
In Partnership With :
QUESTIONS?
Contact us: 1-800-882-8684
Email: enquiry@iqpc.com
©2024 IQPC. All rights reserved.
Brand Advisory Board
Laurie Smaldone
CMO/CSO
NDA Group
John Balchunus
Workforce Director
National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Vera Hoffman
CEO & Co Founder
Reveal Pharma
John McShane
Managing Director
Validant
Anton Xavier
Founder and CEO
K9 Biotech
James Zanewicz
Chief Business Officer
Tulane University
